Cysteine transporter SLC3A1 promotes breast cancer tumorigenesis
Open Access
- 1 January 2017
- journal article
- research article
- Published by Ivyspring International Publisher in Theranostics
- Vol. 7 (4) , 1036-1046
Abstract
Cysteine is an essential amino acid for infants, aged people as well as patients with metabolic disorders. Although the thiol group of cysteine side chain is active in oxidative reactions, the role of cysteine in cancer remains largely unknown. Here, we report that the expression level of the solute carrier family 3, member 1 (SLC3A1), the cysteine carrier, tightly correlated with clinical stages and patients' survival. Elevated SLC3A1 expression accelerated the cysteine uptake and the accumulation of reductive glutathione (GSH), leading to reduced reactive oxygen species (ROS). ROS increased the stability and activity of PP2Ac, resulting in decreased AKT activity. Hence, SLC3A1 activated the AKT signaling through inhibiting PP2A phosphatase activity. Consistently, overexpression of SLC3A1 enhanced tumorigenesis of breast cancer cells, whereas blocking SLC3A1 either with specific siRNA or SLC3A1 specific inhibitor sulfasalazine suppressed tumor growth and also abolished dietary NAC-promoted tumor growth. Collectively, our data demonstrate that SLC3A1 promotes cysteine uptake and determines cellular response to antioxidant N-acetylcysteine, suggesting SLC3A1 is a potential therapeutic target for breast cancer.Keywords
This publication has 34 references indexed in Scilit:
- Oxidants, antioxidants and the current incurability of metastatic cancersOpen Biology, 2013
- Metabolite Profiling Identifies a Key Role for Glycine in Rapid Cancer Cell ProliferationScience, 2012
- Inhibition of Pyruvate Kinase M2 by Reactive Oxygen Species Contributes to Cellular Antioxidant ResponsesScience, 2011
- Functional genomics reveal that the serine synthesis pathway is essential in breast cancerNature, 2011
- Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesisNature Genetics, 2011
- Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?Nature Reviews Drug Discovery, 2009
- HIF-Dependent Antitumorigenic Effect of Antioxidants In VivoCancer Cell, 2007
- Mortality in Randomized Trials of Antioxidant Supplements for Primary and Secondary PreventionJAMA, 2007
- Redox-Dependent Expression of Cyclin D1 and Cell Proliferation by Nox1 in Mouse Lung Epithelial CellsAntioxidants & Redox Signaling, 2006
- Oxidants Painting the Cysteine ChapelDevelopmental Cell, 2002